Best performing Betashares ASX ETFs over the last year

A review of this ETF provider's best performing funds. 

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I am a self-confessed ASX ETF "nuffy". 

I believe it's extremely difficult for individuals (especially new investors) to outperform indexes like the S&P/ASX 200 Index (ASX: XJO) or the S&P 500 Index (SP: .INX) over a long period of time. 

Historically, these indexes have roughly provided annualised returns of 10-12%, depending on which period you look at. 

I believe ASX ETFs give you a simple and cost effective way to buy into these indexes. 

On top of that, sprinkling in a thematic fund or two tailored to a sector you believe can grow and you have a pretty well diversified portfolio. 

However there are plenty of ETF providers and funds to choose from. 

An ETF provider (also known as an ETF issuer) is a financial company that creates, manages, and markets exchange-traded funds (ETFs). 

These providers design the ETF, determine its investment strategy, and are responsible for ensuring it operates according to its objectives.

One of the most common providers is Betashares. 

BetaShares is currently the largest Australian-owned ETF provider on the ASX – in terms of the number of ETFs offered.

With that in mind, let's look at the best performing Betashares ASX ETFs over the past year. 

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today

Image source: Getty Images

Betashares S&P ASX Australian Technology ETF (ASX: ATEC)

The recent success of the Aussie tech sector has been well-documented.

In fact, it even outperformed the US tech sector in FY25. 

It's no surprise that this Betashares tracking Australian technology was the provider's best performing ASX ETF. 

It has risen almost 30% in the last year. 

At the time of writing it provides exposure to 42 leading ASX-listed companies in a range of tech-related market segments such as information technology, consumer electronics, online retail and medical technology.

Its largest holdings include Pro Medicus Ltd (ASX: PME), Xero Ltd (ASX: XRO) and WiseTech Global Ltd (ASX: WTC). 

This fund could be ideal for an investor optimistic about the continued growth of the Australian tech sector. 

BetaShares S&P/ASX 200 Financials Sector ETF (ASX: QFN)

The ASX 200 financials sector was the top-performing market sector of FY25. 

This Betashares ASX ETF was right behind ATEC ETF, rising 23.84% in the past 12 months. 

The success of the fund was driven by its exposure to the largest ASX-listed companies in the financial sector, including the 'Big 4' banks and insurance companies. 

It's worth noting the fund actively excludes Real Estate Investment Trusts (REITs).

Roughly 60% of the fund is made up of the big four banks. 

BetaShares Australian Quality ETF (ASX: AQLT)

AQLT's ETF selects roughly 40 Australian companies based on 'quality' metrics of high return on equity, low leverage and relative earnings stability.

It has tended to have different sector weightings to benchmark Australian equities indices, with higher exposure to sectors such as consumer discretionary and lower exposure to the materials (mining) sector, offering potential portfolio diversification benefits.

The fund is made up of a fairly evenly distributed portfolio. Currently no holding represents more than 6.1% of the fund out of the 39 total. 

It rose almost 16% in the last year. 

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
ASX Share Market News

Record breaker! The ASX 200 just hit a fresh all-time high

Investors just sent the ASX 200 into uncharted territory.

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
ASX Share Market News

Why is everyone talking about Domino's, Light & Wonder and BHP shares on Wednesday?

BHP, Light & Wonder, and Domino’s shares are turning heads today. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »